Strategic Analysis of the European Therapeutic Monoclonal Antibodies (Non-Cancer) Market

 


This report will address the products and molecules currently in phase II to launch phase and their potential applications in the segments highlighted below. It will include products that Frost & Sullivan predict will be launched within the forecast period of 2002 to 2010. The success of a product through phase III trials is obviously not guaranteed, with around a 30 percent failure rate. Therefore, this report must be based on a number of assumptions, all of which will be highlighted throughout. Products already available on the market, as well as competitive situation will be addressed. Each segment will be researched on a European level, with any specific country challenges and trends identified.

Regular Price: USD 4,950

Special Price USD 3,465

30% OFF

* Required Fields

Regular Price: USD 4,950

Special Price USD 3,465

PAY BY INVOICE

Be the first to review this product

Table of Contents

Strategic Analysis of the European Therapeutic Monoclonal Antibodies (Non-Cancer) Market, Executive SummaryMarket OverviewIntroduction and PresentationStrategic Analysis of the European Therapeutic Monoclonal Antibodies (Non-Cancer) Market, Monoclonal Antibodies - OverviewTherapeutic MabsOverviewTechnology TrendsAcronymsAcronymsStrategic Analysis of the European Therapeutic Monoclonal Antibodies (Non-Cancer) Market, Challenges Affecting the Therapeutic Monoclonal Antibodies MarketIdentification of the Challenges Facing the European Therapeutic Monoclonal Antibodies MarketTotal Market ChallengesStrategic Analysis of the European Therapeutic Monoclonal Antibodies (Non-Cancer) Market, Strategic Assessment of the European Therapeutic Monoclonal Antibodies MarketMarket Engineeing Strategic RecommendationsFormation of Alliances between Biotech and PharmaTechnology DevelopmentPharmacoeconomic Analysis Comparative StudiesEnd Points and License IndicationsManufacturing Strategies Product DifferentiationPatient AdvocacyStrategic Analysis of the European Therapeutic Monoclonal Antibodies (Non-Cancer) Market, Research and DevelopmentOverview of the Current SituationR and D: Autoimmune and Inflammatory DiseaseR and D: Organ TransplantR and D: Cardiovascular DisordersR and D: Infectious DiseaseKey Companies and Research and Marketing CollaborationsOverviewAbgenixAbgenix and SangstatAlexion and Proctor & GambleCAT and AbbottCelltech and BiogenCelltech and PharmaciaCentecor and Eli LillyElan and BiogenGenentech Xoma and SeronoGenmabIDEC PharmaceuticalsMedarexMedimmune Millennium NovartisRoche and PDLSerono and GenentechSchering PloughRecent Research CollaborationsAbbott and MedarexChugai and AbgenixMorphoSys and Boehringer IngelheimOverview of Products in Late Stage Development for Autoimmune DiseaseElan/Biogen: AntegrenCelltech/Pharmacia: CDP 870CAT/Abbott: Humara Celltech/Biogen: HumicadeILEX Oncology: CAMPATHMedimmune/Biotransplant: Siplizumab (MEDI-507)Protein Design Labs/Roche: DaclizumabRoche: MabThera (Rituximab)Alexion: EculizumabGenentech/Xoma: RaptivaGenentech/Novartis/Tanox: XolairGenmab/Amgen: HuMax IL15Genmab: HuMax CD4Overview of Products in Late Stage Development for Organ TransplantAbgenix/Sangstat: ABX-CBL - DiscontinuedProtein Design Labs: NuvionRoche: ZenapaxOverview of Products in Development (Other Disease Areas)Alexion/P&G: PexelizumabEli Lilly: ReoproMarket Engineering Research for the Total European Therapeutic Monoclonal Antibodies Market Market OverviewMarket Challenges R and D FocusPotential Treatable Population - AssumptionsForecasting AssumptionsPredicted Launches - AssumptionsMarket ForecastsMarket Engineering Research Measurement SystemMarket Drivers Market RestraintsMarket Engineering Revenue Forecasts Revenue Trends by SegmentPricing & Reimbursement IssuesCompetitive AnalysisCompetitive Situation Market Engineering Research for the European Therapeutic Monoclonal Antibodies Market for Use in Autoimmune and Inflammatory DiseaseDisease and Treatment OverviewMarket OverviewPsoriasisRheumatoid ArthritisMultiple SclerosisCrohn's DiseaseAsthma/AllergyEpidemiology and Potential Treatable PopulationPsoriasisRheumatoid ArthritisMultiple SclerosisCrohn's DiseaseAsthmaCountry Specific IssuesUnited KingdomFranceMarket ForecastsMarket Engineering Research Measurement SystemMarket Drivers Market RestraintsOverview of Marketed MabsMarket Potential by DiseaseForecasts for the Total Market Major Product ForecastsAntegren Market Forecast Remicade Revenue ForecastsHumara Revenue ForecastsCDP 870 Revenue ForecastsRaptiva Revenue ForecastsXolair Revenue Forecasts Competitive AnalysisFuture Competitive Situation Overview of Competitive Products in RAOverview of Competitive Products in MSOverview of Competitive Products in PsoriasisMarket Engineering Research for the European Therapeutic Monoclonal Antibodies Market for Use in Organ TransplantMarket OverviewSummaryDisease and Treatment OverviewEpidemiology and Potential Treatable PopulationMarket ForecastsMarket Drivers Market RestraintsOverview of Marketed Monoclonal AntibodiesPricingMarket PotentialForecasting AssumptionsTotal Revenue ForecastsProduct Trends and UptakeSimulect Zenapax Nuvion Competitive AnaylsisCompetitive SituationOverview of Competitive ProductsStrategic Analysis of the European Therapeutic Monoclonal Antibodies (Non-Cancer) Market, Overview of the European Therapeutic Monoclonal Antibodies Market for Use in Cardiovascular Disorders OverviewIntroduction to Cardiovascular DiseaseCardiovascular Disease Areas of InterestEpidemiology Current and Future Market SituationMarket Drivers and Restraints Overview of Reopro Research & Development ActivitiesReopro Market Potential and Forecast Pexelizumab Market Potential and ForecastCompetitive SituationFuture Competitive EnvironmentStrategic Analysis of the European Therapeutic Monoclonal Antibodies (Non-Cancer) Market, Overview of the European Therapeutic Monoclonal Antibodies Market for Use in Infectious DiseaseMarket OverviewIntroductionRespiratory Syncticial Virus - Overview and TreatmentPotential Treatable Population in RSVCurrent & Future Market SituationMarket Opportunities and Challenges Overview of SynagisCost-Benefit Analysis of SynagisResearch and Development Activities Synagis Market Potential and Revenue ForecastStrategic Analysis of the European Therapeutic Monoclonal Antibodies (Non-Cancer) Market, Market Engineering Awards For the European Therapeutic Monoclonal Antibodies MarketMarket Engineering AwardsMarket Engineering Awards 2003 Product Innovation Award




Related Research

Release Date : 22-Aug-17

Region : Europe

Release Date : 16-Aug-17

Region : Europe

Release Date : 16-Aug-17

Region : Europe

Release Date : 11-Aug-17

Region : Europe

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.